Search

everythinglearnresearchcommunity

for

Search:↓

Human dermal fibroblasts are the main cells targeted by a virus that can cause a deadly skin cancer, and a certain inhibitor can effectively block this infection.

Increased Toll-like receptors in blood cells may contribute to alopecia areata and could be a target for new treatments.

Alopecia areata patients have higher levels of certain immune receptors, suggesting new treatment possibilities.

Longer immunotherapy treatment may improve outcomes for Merkel cell carcinoma patients.

Telitacicept effectively improved hair regrowth in a woman with lupus and alopecia.

A new test helps find drugs to treat head and neck cancer by targeting c-Rel.

Alopecia areata is an autoimmune disease where T cells attack hair follicles.

A man developed a skin cancer called folliculotropic mycosis fungoides after a kidney transplant.

Increasing regulatory T cells may help treat alopecia areata by reducing autoimmunity and promoting hair growth.

Telocytes have potential in therapy and tissue regeneration, but challenges in identification and cultivation remain.

CD44 variant changes start alopecia areata, but don't maintain it.

People with Alopecia areata have higher levels of certain T regulatory cells in their blood.

Deleting the MAD2L1 gene is tolerated in certain mouse cancer models.

Genetic mutation and carcinogen treatment are both needed for skin cancer to develop in these specific mice.

Abnormal T-cells from thymomas cause non-motor symptoms in some myasthenia gravis patients.

A substance called poly(I:C) increases a protein called carbonic anhydrase II in skin cells, which might help with skin defense and healing.

TICE salvage chemotherapy is effective for treating germ-cell tumors with poor prognosis.

Tofacitinib helped most patients with alopecia areata regrow hair and changes in immune cells were linked to the treatment's effectiveness.

A parasite-derived molecule speeds up skin healing and affects immune cell behavior without increasing scarring.

Three characteristics of plasmacytoid dendritic cells help tell apart lupus-related hair loss from LPP.

Certain immune markers may predict chemotherapy response in mesothelioma, and nivolumab is a tolerable and effective treatment for advanced non-small cell lung cancer.

Interferon alfa-2a is effective for treating cutaneous T cell lymphoma but has significant side effects.

Tocilizumab therapy may cause skin and hair conditions like halo naevi, vitiligo, and alopecia areata.

BST2 protein and certain T cells increase in early alopecia areata.

Higher levels of certain immune cells in hair follicles may contribute to alopecia areata.

Thymoma with alopecia areata may be linked to abnormal immune cells.

Merkel cell polyomavirus can infect and persist in skin cells, evading the immune system, but certain treatments can control it.

MC-DNA vector-based gene therapy can temporarily treat CBS deficiency in mice.

Folliculotropic mycosis fungoides can affect the central nervous system in advanced stages.